

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



IVD Medical Holding Limited

華檢醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1931)

INSIDE INFORMATION

POSITIVE PROFIT ALERT FOR THE SIX MONTHS ENDED 30 JUNE 2019

This announcement is made by IVD Medical Holding Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the latest available information and a preliminary assessment of the Group’s unaudited consolidated management accounts, it is expected that the Group will record a significant increase in revenue by approximately 400% and a significant increase in profit attributable to owners of the parent of the Group by approximately 650% (taking into account of the listing expenses incurred during the six months ended 30 June 2019), respectively, for the six months ended 30 June 2019 as compared to those of the revenue and profit attributable to owners of the parent of the Group, respectively, for the six months ended 30 June 2018.

Reference is made to the prospectus of the Company dated 29 June 2019 (the “**Prospectus**”). The Board considers that the significant increase in revenue and profit attributable to owners of the parent of the Group, respectively, for the six months ended 30 June 2019 was primarily attributable to (i) the consolidation of the financial results of Vastec Medical Limited (“**Vastec**”) together with its subsidiaries after the completion of the acquisition of 60% shareholding interest in Vastec in January 2019 (the “**Acquisition**”); and (ii) a gain on remeasurement of previously held interest in Vastec of approximately RMB218 million relating to the Acquisition. Details of the Acquisition were set out in the Prospectus.

As at the date of this announcement, the Group is still in the process of preparing its unaudited consolidated interim results for the six months ended 30 June 2019 and is not able at this time to disclose any further details on the above factors. The information contained in this announcement is only based on the Board's preliminary assessment with reference to the unaudited consolidated management accounts of the Group for the six months ended 30 June 2019 and information currently available to the Board, which has not been reviewed or confirmed by the Company's auditors and/or the audit committee of the Company and is subject to changes. Shareholders and potential investors should refer to and review the unaudited consolidated interim results for the six months ended 2019, which will be published by the Company pursuant to the requirements of the Listing Rules.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
IVD Medical Holding Limited
Ho Kuk Sing
Chairman and Executive Director

Hong Kong, 16 July 2019

As at the date of this announcement, the Board comprises of three executive directors, namely, Mr. Ho Kuk Sing, Mr. Leung King Sun and Mr. Lin Xianya, three non-executive directors, namely, Mr. Chen Xingang, Mr. Yang Zhaoxu, and Mr. Chan Kwok King, Kingsley and three independent non-executive directors, namely, Mr. Lau Siu Ki, Mr. Zhong Renqian and Mr. Leung Ka Sing.